Bentley Pharmaceuticals to Present at the CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference on April 4, 2006

Business Wire, March 16, 2006

EXETER, N.H. -- Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical and drug delivery company, announced today that Fred Feldman, Ph.D., Vice President of Research and Development and Robert Stote, MD, FACP, Chief Medical Officer, will present at the CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference taking place at the Millennium Broadway Hotel in New York City. Bentley's presentation of "New Drug Delivery Potentials for Treatment of Diabetes" is scheduled for Tuesday, April 4, 2006 at 3:15 p.m. (Eastern Standard Time).

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures a growing portfolio of generic and branded pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiary, Laboratorios Belmac, and markets these pharmaceutical products through its subsidiaries, Laboratorios Belmac, Laboratorios Davur, Laboratorios Rimafar and Bentley Pharmaceuticals Ireland; and manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API.

Copies of Bentley Pharmaceuticals' press releases and other information may be obtained through Bentley's web site at www.bentleypharm.com.